Evergreen Capital Management LLC Boosts Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Evergreen Capital Management LLC significantly increased its stake in United Therapeutics Corporation by 806.8%, acquiring an additional 10,908 shares, bringing its total holdings to 12,260 shares valued at approximately $3.78 million.
• Analysts have set varying price targets for United Therapeutics, with firms like Morgan Stanley and Wells Fargo reducing their targets, while HC Wainwright maintains a buy rating with a target of $400.00.
• United Therapeutics recently reported earnings of $6.41 per share, missing analyst expectations, but showed a year-over-year revenue increase of 11.7% to $798.6 million.

Evergreen Capital Management LLC grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 806.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,260 shares of the biotechnology company's stock after acquiring an additional 10,908 shares during the period. Evergreen Capital Management LLC's holdings in United Therapeutics were worth $3,779,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. XTX Topco Ltd bought a new position in United Therapeutics during the 1st quarter valued at about $313,000. Allianz Asset Management GmbH lifted its stake in United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after acquiring an additional 33,254 shares during the last quarter. LPL Financial LLC lifted its stake in United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after acquiring an additional 11,007 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $227,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $100.05 during trading on Tuesday, hitting $404.81. The company's stock had a trading volume of 3,141,718 shares, compared to its average volume of 547,665. The stock has a market cap of $18.26 billion, a price-to-earnings ratio of 15.80, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62. The stock has a 50-day moving average price of $299.03 and a two-hundred day moving average price of $304.77. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period last year, the company earned $5.85 EPS. United Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 84,681 shares of company stock worth $25,807,469 over the last 90 days. Corporate insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. JPMorgan Chase & Co. cut their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday. UBS Group lifted their price target on United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. Finally, Wells Fargo & Company dropped their target price on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $403.54.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.